Description
Stenabolic SR9009 10 mg Swiss Pharmaceuticals — stenabolic (SR-9009) from Swiss Pharmaceuticals at 10 mg. Rev-Erb agonist (not a SARM). Drives mitochondrial biogenesis and fat-oxidation. Short half-life requires multiple daily doses.
Key Benefits
- Rev-erbα agonist — modulates circadian metabolism
- Improves endurance via mitochondrial biogenesis
- Not a SARM (no AR binding) despite common grouping
- Oral dosing; short half-life requires 3–4× daily
- Zero HPTA impact, no PCT required
- Each unit dosed at 10 mg — see Recommended Dosage below for protocol-specific intake
Recommended Dosage
Research dosing: 20–40 mg/day split 3–4× daily (every 4 hours) due to short half-life. Cycles 8 weeks. Oral bioavailability poor — injectable research-grade versions show higher effective exposure.
How It Works
Synthetic Rev-erbα/β agonist. Modulates the mammalian circadian clock at the transcriptional level, shifting muscle-fibre metabolism toward oxidative phenotype. Upregulates mitochondrial biogenesis and fatty-acid oxidation without AR interaction.
Pharmacokinetics
Plasma half-life approximately 4 hours — frequent dosing required for continuous exposure. Oral bioavailability limited (extensive first-pass metabolism). Store tablets dry and cool.
Potential Side Effects
Clean profile at research doses. No HPTA impact. Sleep architecture can shift with dosing schedule — avoid late-evening doses. Limited long-term safety data.
Cycle & Stacking Guide
8-week protocols during endurance-focused training phases. Stacks with cardarine for cardiovascular performance or with SARMs for body-recomposition support.
Manufacturer Notes
Swiss Pharmaceuticals is a research-compound producer with published batch QC data. Vials ship with tamper-evident caps and date-coded labels.
Storage & Handling
Store at recommended temperature (15–25°C; peptides and HGH at 2–8°C after reconstitution). Protect from light and moisture. Keep out of reach of children. For research and educational purposes only.
Reviews
There are no reviews yet.